XML 47 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
The Company and Summary of Significant Accounting Policies (Details) (USD $)
 1 Months Ended 3 Months Ended 9 Months Ended 141 Months Ended
Mar. 04, 2013
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Patients
Sep. 30, 2012
Sep. 30, 2013
Company Development Stage and Basis of Presentation (Textual) [Abstract]            
Anticipated time to start AF Trial       168 days    
Number of patients company plans to enroll       200    
Number of years to complete the study       2 years 6 months    
Reverse stock split 1-for-6 reverse split          
Loss from operations   $ (1,725,000) $ (928,000) $ (3,993,000) $ (3,480,000) $ (103,136,000)
Cash flows from operations       (3,416,000) (3,408,000) (100,837,000)
Revenue generated by the company           $ 0
Phase 3 heart failure (HF) trial of Gencaro
            
Company Development Stage and Basis of Presentation (Textual) [Abstract]            
Number of patients       2,708    
Number of patients company plans to enroll       420